Charych Deborah H. 4

What Happened
Deborah H. Charych, a director of Skye Bioscience, was granted a derivative award of 35,000 shares (coded as an award/acquisition) on Feb 6, 2026. The Form 4 reports an acquisition price of $0.00, indicating an awarded stock option rather than a market purchase or sale. No cash changed hands at grant.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (timely filing).
• Grant: 35,000 derivative shares (stock option award) at $0.00 per share.
• Vesting: footnote states the stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.
• Shares owned after transaction: not specified in this filing.
• No 10b5-1 plan, tax withholding, or sale reported in this Form 4.

Context
This was an award of stock options (a derivative grant) that vests over time—there was no immediate purchase or sale. Such grants compensate insiders and align them with long-term stock performance; they do not by themselves indicate buying or selling sentiment. Future value depends on the option terms and the company’s share price when/if options are exercised.